Season 25 · Episode 28
Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Breast Cancer Update · Dr. Neil Love
September 1, 202515m 43s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events with available antibody-drug conjugates and novel strategies incorporating ADCs into the breast cancer treatment paradigm.
CME information and select publications here.